Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2007

01-09-2007 | EPIDEMILOGY

Margin status and the risk of local recurrence after breast-conserving treatment of lobular breast cancer

Authors: N. van den Broek, M. J. C. van der Sangen, L. V. van de Poll-Franse, M. W. P. M. van Beek, G. A. P. Nieuwenhuijzen, A. C. Voogd

Published in: Breast Cancer Research and Treatment | Issue 1/2007

Login to get access

Abstract

Background Invasive lobular breast carcinoma is known for its multicentricity and is associated with a higher incidence of incomplete excision after breast-conserving therapy. The aim of the study was to examine the influence of positive surgical margins on the local recurrence rate in patients diagnosed with invasive lobular cancer and treated with breast-conserving therapy. Methods All 416 women diagnosed with invasive lobular breast cancer and undergoing breast-conserving treatment between 1995 and 2002 were selected from the population-based Eindhoven Cancer Registry. Their medical charts were reviewed and detailed information was collected. Results The risk of margin involvement was 29% after the first operation and 17% when taking into account the final margin status of the patients undergoing re-excision. During follow-up, 18 patients developed a local recurrence. The 5 year actuarial risk of developing a local recurrence was 3.5% (95% confidence interval 2.5–4.5) and the 8 year risk was 6.4% (95% confidence interval 4.7–8.0). There was no influence of positive surgical margins on the risk of local recurrence, neither in the univariate analysis nor after adjustment for age, tumour size, nodal status and adjuvant systemic treatment. Conclusion Patients with invasive lobular cancer, treated with breast-conservation, have a low risk of local recurrence, despite their high risk of having a microscopically incomplete excision of the tumour.
Literature
1.
The World Health Organization Histological Typing of Breast Tumors–Second Edition (1982) The World Organization. Am J Clin Pathol 78(6):806–816
2.
Wellings SR, Jensen HM, Marcum RG (1975) An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 55(2):231–273PubMed
3.
Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC (1975) The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 36(1):1–85PubMedCrossRef
4.
Martinez V, Azzopardi JG (1979) Invasive lobular carcinoma of the breast: incidence and variants. Histopathology. 3(6):467–488PubMedCrossRef
5.
Verkooijen HM, Fioretta G, Vlastos G et al. (2003) Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 104(6):778–81
6.
Li CI, Anderson BO, Daling JR, Moe RE (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289(11):1421–1424PubMedCrossRef
7.
Sastre-Garau X, Jouve M, Asselain B, et al. (1996) Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 77(1):113–120PubMedCrossRef
8.
Yeatman TJ, Cantor AB, Smith TJ et al. (1995) Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg 222(4):549–559; discussion. 559–561
9.
Silverstein MJ, Lewinsky BS, Waisman JR, Gierson ED, Colburn WJ, Senofsky GM et al. (1994) Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer. 73(6):1673–1677PubMedCrossRef
10.
Moore MM, Borossa G, Imbrie JZ et al. (2000) Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy. Ann Surg 231(6):877–882PubMedCrossRef
11.
Peiro G, Bornstein BA, Connolly JL (2000) The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat 59(1):49–54PubMedCrossRef
12.
Chung MA, Cole B, Wanebo HJ, Bland KI, Chang HR (1997) Optimal surgical treatment of invasive lobular carcinoma of the breast. Ann Surg Oncol 4(7):545–550PubMedCrossRef
13.
Singletary SE, Patel-Parekh L, Bland KI (2005) Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base. Ann Surg 242(2):281–289PubMedCrossRef
14.
Holland PA, Shah A, Howell A, Baildam AD, Bundred NJ (1995) Lobular carcinoma of the breast can be managed by breast-conserving therapy. Br J Surg 82(10):1364–1366PubMedCrossRef
15.
Bouvet M, Ollila DW, Hunt KK, Babiera GV et al. (1997) Role of conservation therapy for invasive lobular carcinoma of the breast. Ann Surg Oncol 4(8):650–654PubMedCrossRef
16.
Kurtz JM, Jacquemier J, Torhorst J et al. (1989) Conservation therapy for breast cancers other than infiltrating ductal carcinoma. Cancer 63(8):1630–1635PubMedCrossRef
17.
Schnitt SJ, Connolly JL, Recht A, Silver B, Harris JR (1989) Influence of infiltrating lobular histology on local tumor control in breast cancer patients treated with conservative surgery and radiotherapy. Cancer 64(2):448–454PubMedCrossRef
18.
Poen JC, Tran L, Juillard G et al. (1992) Conservation therapy for invasive lobular carcinoma of the breast. Cancer 69(11):2789–2795PubMedCrossRef
19.
Salvadori B, Biganzoli E, Veronesi P, Saccozzi R, Rilke F (1997) Conservative surgery for infiltrating lobular breast carcinoma. Br J Surg 84(1):106–109PubMedCrossRef
20.
White JR, Gustafson GS, Wimbish K et al. (1994) Conservative surgery and radiation therapy for infiltrating lobular carcinoma of the breast. The role of preoperative mammograms in guiding treatment. Cancer 74(2):640–647PubMedCrossRef
21.
Mai KT, Yazdi HM, Isotalo PA (2000) Resection margin status in lumpectomy specimens of infiltrating lobular carcinoma. Breast Cancer Res Treat 60(1):29–33PubMedCrossRef
22.
Morrow M, Keeney K, Scholtens D, Wei J, Steel J, Khan SA (2006) Selecting patients for breast-conserving therapy: the importance of lobular histology. Cancer 106(12):2563–2568PubMedCrossRef
23.
Newman LA, Kuerer HM (2005) Advances in breast conservation therapy. J Clin Oncol 23(8):1685–1697PubMedCrossRef
24.
Voogd AC, Nielsen M, Peterse JL et al. (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol1.9(6):1688–1697
25.
Rutgers EJ, Nortier JW, Tuut MK et al. (2002) [Dutch Institute for Healthcare Improvement guideline, “Treatment of breast cancer”]. Ned Tijdschr Geneeskd 146(45):2144–2151PubMed
Metadata
Title
Margin status and the risk of local recurrence after breast-conserving treatment of lobular breast cancer
Authors
N. van den Broek
M. J. C. van der Sangen
L. V. van de Poll-Franse
M. W. P. M. van Beek
G. A. P. Nieuwenhuijzen
A. C. Voogd
Publication date
01-09-2007
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9431-5

Other articles of this Issue 1/2007

Breast Cancer Research and Treatment 1/2007 Go to the issue

Epidemiology

Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival

Pre-clinical Study

Pathologic examination of sentinel lymph nodes in breast cancer by a single haematoxylin-eosin slide versus serial sectioning and immunocytokeratin staining: clinical implications

Clinical Epidemiology

Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study

Epidemiology

Associations between the CYP17, CYPIB1, COMT and SHBG polymorphisms and serum sex hormones in post-menopausal breast cancer survivors

Critical Trial

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer

Original Paper

Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits